Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Recruiting now
Conditions studied: Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients
In brief
Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors. While effective, they can cause immune-related side effects, including liver inflammation (ICI-induced hepatitis or CHILI), which affects up to 25% of patients. Severe cases requiring treatment discontinuation are rare but challenging to manage. Study Objective This multicenter prospective study aims to better understand CHILI, its clinical patterns, treatment response, and risk of recurrence. It will focus on different types of liver injury (cholestatic, hepatocellular, or mixed) to guide better treatment decisions. Innovation and Approach Currently, there is no clear consensus on how to manage CHILI or when to safely restart immunotherapy. This study will collect real-world data from adult patients treated with ICIs, following international guidelines or a pragmatic approach when no consensus exists. Findings will help improve care strategies for patients experiencing ICI-related liver toxicity.
Key facts
- Study ID
- NCT06864481
- Run by
- University Hospital, Montpellier
- People needed
- 250
- Starts
- 2025-04-22
- Expected to finish
- 2028-04-22
- Last updated by the study team
- 2026-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- Patient willing to participate in the study
- Patient with cancer receiving neoadjuvant, adjuvant, or maintenance treatment · Patient treated with ICI, either as monotherapy or in combination with another antitumor treatment (targeted therapy, chemotherapy, or radiotherapy), either de novo or after a first-line treatment including ICIs
- Patient who has received at least one injection of an ICI ·
- Onset of hepatitis following treatment initiation, defined by the following criteria:
- ALT (alanine aminotransferase) ≥ 5 times the upper normal limit
- ALP (alkaline phosphatase) ≥ 2 times the upper normal limit
- ALT (alanine aminotransferase) ≥ 3 times the upper normal limit and bilirubin ≥ 2 times the upper normal limit ·
- Patient with grade 3 or 4 hepatitis, according to the current CTCAE classification
- Exclusion criteria:
- Patient with another cause of acute hepatitis, including viral, autoimmune, ischemic, acute alcoholic hepatitis, or Wilson's disease.
- Patient unable to express their non-opposition to participate in the study.
- Person deprived of liberty, under guardianship or curatorship, or in an emergency situation.
- Person not affiliated with a social security system or without entitlement to healthcare coverage.
Where it is running
- Montpellier University Hospital — Montpellier, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.